心血管疾病与 COVID-19：危险的关联。
Cardiovascular disease and COVID-19: les liaisons dangereuses.
机构信息
Cardiology Division, Fondazione Toscana Gabriele Monasterio, Italy.
Insitute of Life Sciences, Scuola Superiore Sant'Anna, Italy.
出版信息
Eur J Prev Cardiol. 2020 Jul;27(10):1017-1025. doi: 10.1177/2047487320924501. Epub 2020 May 11.
Abstract
Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.
摘要
患有心血管危险因素或已患有心血管疾病的患者罹患 19 型冠状病毒病的风险增加，感染后预后更差，但将这一概念转化为有效行动具有挑战性。目前尚不清楚心血管治疗是否可以降低感染的可能性，或者提高感染患者的生存率。鉴于这一问题对临床心脏病专家和所有处理 19 型冠状病毒病的专家至关重要，我们试图总结当前的证据并提供一些实用建议。
相似文献
1
Cardiovascular disease and COVID-19: les liaisons dangereuses.心血管疾病与 COVID-19：危险的关联。
Eur J Prev Cardiol. 2020 Jul;27(10):1017-1025. doi: 10.1177/2047487320924501. Epub 2020 May 11.
2
Editor's presentation: 'Les liaisones dangerouses. The heart in the time of COVID-19'.编辑介绍：《危险关系。新冠疫情下的心脏》
Eur J Prev Cardiol. 2020 Jul;27(10):1011-1013. doi: 10.1177/2047487320936413.
3
Cardiovascular Implications of COVID-19 Infections.新型冠状病毒肺炎感染的心血管影响
Methodist Debakey Cardiovasc J. 2020 Apr-Jun;16(2):146-154. doi: 10.14797/mdcj-16-2-146.
4
[ANMCO Position paper: Cardiological outpatient activities in the transition phase of the COVID-19 pandemic].[意大利心脏病学会立场文件：新冠疫情过渡阶段的心脏病门诊活动]
G Ital Cardiol (Rome). 2020 Aug;21(8):584-588. doi: 10.1714/3405.33889.
5
A close-up on COVID-19 and cardiovascular diseases.聚焦 COVID-19 与心血管疾病。
Nutr Metab Cardiovasc Dis. 2020 Jun 25;30(7):1057-1060. doi: 10.1016/j.numecd.2020.04.001. Epub 2020 Apr 8.
6
At the heart of COVID-19.新冠病毒的核心
J Card Surg. 2020 Jun;35(6):1287-1294. doi: 10.1111/jocs.14596. Epub 2020 May 5.
7
[ANMCO Position paper: Role of cardiology in the management of health needs in the post-COVID-19 era].[意大利心脏病学与心血管外科学会立场文件：心脏病学在新冠疫情后时代健康需求管理中的作用]
G Ital Cardiol (Rome). 2020 Jul;21(7):509-513. doi: 10.1714/3386.33636.
8
How is the cardiovascular patient managed during Covid-19 pandemic? A report from the frontline.在新冠疫情期间如何管理心血管疾病患者？来自一线的报告。
Catheter Cardiovasc Interv. 2020 Nov;96(5):E565. doi: 10.1002/ccd.28966. Epub 2020 May 20.
9
Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective.《COVID-19 大流行对心血管的影响：全球视角》
Can J Cardiol. 2020 Jul;36(7):1068-1080. doi: 10.1016/j.cjca.2020.05.018. Epub 2020 May 16.
10
CSANZ Position Statement on COVID-19 From the Paediatric and Congenital Council.CSANZ 关于 COVID-19 的立场声明来自儿科和先天性委员会。
Heart Lung Circ. 2020 Sep;29(9):e217-e221. doi: 10.1016/j.hlc.2020.07.005. Epub 2020 Jul 29.
引用本文的文献
1
Latin-American guidelines of recommendations at discharge from an acute coronary syndrome.拉丁美洲急性冠状动脉综合征出院推荐指南。
Arch Cardiol Mex. 2024;94(Supl 2):1-52. doi: 10.24875/ACM.M24000096.
2
Digital health for remote home monitoring of patients with COVID-19 requiring oxygen: a cohort study and literature review.用于对需要吸氧的新冠肺炎患者进行远程居家监测的数字健康：一项队列研究及文献综述
Front Med (Lausanne). 2024 Jan 31;10:1255798. doi: 10.3389/fmed.2023.1255798. eCollection 2023.
3
[Cardiac tele-rehabilitation in times of pandemic. Experience at the National Cardiovascular Institute INCOR in Lima-Peru].[大流行时期的心脏远程康复。秘鲁利马国家心血管研究所（INCOR）的经验]
Arch Peru Cardiol Cir Cardiovasc. 2023 Mar 31;4(1):13-20. doi: 10.47487/apcyccv.v4i1.281. eCollection 2023 Jan-Mar.
4
Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation.由于 LMNA 基因 p.R349W 突变导致部分脂肪营养不良的 SARS-CoV-2 感染后的心脏后急性并发症。
J Endocrinol Invest. 2022 Aug;45(8):1569-1575. doi: 10.1007/s40618-022-01795-6. Epub 2022 Apr 6.
5
Post-COVID-19 Pulmonary Fibrosis.新型冠状病毒肺炎后肺纤维化
Cureus. 2022 Mar 2;14(3):e22770. doi: 10.7759/cureus.22770. eCollection 2022 Mar.
6
The Potential Impact of COVID-19 Virus on the Heart and the Circulatory System.新冠病毒对心脏及循环系统的潜在影响。
Infect Drug Resist. 2022 Mar 22;15:1175-1189. doi: 10.2147/IDR.S351318. eCollection 2022.
7
Subphenotyping of Mexican Patients With COVID-19 at Preadmission To Anticipate Severity Stratification: Age-Sex Unbiased Meta-Clustering Technique.COVID-19 墨西哥患者入院前亚表型分析以预测严重程度分层：年龄性别无偏荟萃聚类技术。
JMIR Public Health Surveill. 2022 Mar 30;8(3):e30032. doi: 10.2196/30032.
8
The Identikit of Patient at Risk for Severe COVID-19 and Death: The Dysregulation of Renin-Angiotensin System as the Common Theme.重症 COVID-19 和死亡风险患者的特征概述：肾素-血管紧张素系统失调作为共同主题
J Clin Med. 2021 Dec 15;10(24):5883. doi: 10.3390/jcm10245883.
9
[Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety].[新型冠状病毒2019感染的治疗：药物相互作用和安全性的回顾性研究]
Ann Pharm Fr. 2022 Jul;80(4):531-542. doi: 10.1016/j.pharma.2021.11.001. Epub 2021 Nov 5.
10
Adverse Cardiovascular Effects of Anti-COVID-19 Drugs.抗新冠病毒药物的心血管不良影响。
Front Pharmacol. 2021 Aug 25;12:699949. doi: 10.3389/fphar.2021.699949. eCollection 2021.
本文引用的文献
1
COVID-19 with Different Severities: A Multicenter Study of Clinical Features.不同严重程度的 COVID-19：一项多中心临床特征研究。
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388. doi: 10.1164/rccm.202002-0445OC.
2
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.2019 冠状病毒病（COVID-19）的重症监护管理：挑战与建议。
Lancet Respir Med. 2020 May;8(5):506-517. doi: 10.1016/S2213-2600(20)30161-2. Epub 2020 Apr 6.
3
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
4
COVID-19 and the Heart.新型冠状病毒肺炎与心脏
Circ Res. 2020 May 8;126(10):1443-1455. doi: 10.1161/CIRCRESAHA.120.317055. Epub 2020 Apr 7.
5
The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design.希腊研究科维德-19 并发症预防中的秋水仙碱作用（GRECCO-19 研究）：原理和研究设计。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):42-45. doi: 10.1016/j.hjc.2020.03.002. Epub 2020 Apr 3.
6
Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.严重新型冠状病毒肺炎与非新型冠状病毒肺炎患者凝血功能特征的差异。
J Thromb Thrombolysis. 2021 May;51(4):1107-1110. doi: 10.1007/s11239-020-02105-8.
7
The Variety of Cardiovascular Presentations of COVID-19.新型冠状病毒肺炎的心血管表现多样性
Circulation. 2020 Jun 9;141(23):1930-1936. doi: 10.1161/CIRCULATIONAHA.120.047164. Epub 2020 Apr 3.
8
Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up.2019 年冠状病毒病在老年患者中的特征和预后因素：基于 4 周随访的研究。
J Infect. 2020 Jun;80(6):639-645. doi: 10.1016/j.jinf.2020.03.019. Epub 2020 Mar 30.
9
Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.新冠病毒肺炎住院患者基础疾病的患病率：一项系统评价与Meta分析
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35. eCollection 2020.
10
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
Zotero 插件